<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2565-005X</journal-id>
<journal-title><![CDATA[Gaceta mexicana de oncología]]></journal-title>
<abbrev-journal-title><![CDATA[Gac. mex. oncol.]]></abbrev-journal-title>
<issn>2565-005X</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Oncología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2565-005X2022000500102</article-id>
<article-id pub-id-type="doi">10.24875/j.gamo.22000005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Cirugía citorreductora radical + quimioterapia intraperitoneal hipertérmica (HIPEC) en carcinomatosis peritoneal por cáncer de ovario]]></article-title>
<article-title xml:lang="en"><![CDATA[Hyperthermic intraperitoneal chemotherapy (HIPEC) + Cytoreductive surgery in ovarian cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cervantes-Zamora]]></surname>
<given-names><![CDATA[Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Prieto]]></surname>
<given-names><![CDATA[Mario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Félix-Guzmán]]></surname>
<given-names><![CDATA[Ulises]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orozco-Orduña]]></surname>
<given-names><![CDATA[Carlos U.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Madrigal-Pérez]]></surname>
<given-names><![CDATA[Violeta M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona 67 Servicio de Cirugía Oncológica]]></institution>
<addr-line><![CDATA[Monterrey N.L]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona 67 Servicio de Oncología Médica]]></institution>
<addr-line><![CDATA[Monterrey N.L]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona 67 Servicio de Ginecología Oncológica]]></institution>
<addr-line><![CDATA[Monterrey N.L]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona 67 Servicio de Anestesiología]]></institution>
<addr-line><![CDATA[Monterrey N.L]]></addr-line>
<country>México</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Hospital General de Zona 67 Servicio de Cirugía General]]></institution>
<addr-line><![CDATA[Monterrey N.L]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2022</year>
</pub-date>
<volume>21</volume>
<fpage>102</fpage>
<lpage>104</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2565-005X2022000500102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2565-005X2022000500102&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2565-005X2022000500102&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El cáncer de ovario es la quinta causa muerte por cáncer y la prevalencia con metástasis peritoneal es alta, con una posibilidad de curación baja.  Presentación de caso: Paciente de 33 años con cáncer de ovario y metástasis peritoneal tratada con cirugía citorreductora radical + quimioterapia intraperitoneal hipertérmica y libre de enfermedad a dos años de seguimiento.  Discusión: Hay evidencia de aumento de supervivencia con la quimioterapia intraperitoneal, con reducción del 21% de riesgo de muerte.  Conclusión: Este tratamiento se puede aplicar como una opción prometedora y posiblemente curativa para esta enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Ovarian cancer is the fifth leading cause of cancer death and the prevalence with peritoneal metastasis is high, with a low possibility of cure.  Case presentation: 33-year-old patient with ovarian cancer and peritoneal metastasis treated with Radical Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy and disease-free at 2 years of follow-up.  Discussion: There is evidence of increased survival of intraperitoneal chemotherapy, with a 21% reduction in the risk of death.  Conclusion: This treatment can be applied as a promising and possibly curative option for this disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Carcinomatosis]]></kwd>
<kwd lng="es"><![CDATA[Cáncer]]></kwd>
<kwd lng="es"><![CDATA[Ovario]]></kwd>
<kwd lng="es"><![CDATA[HIPEC]]></kwd>
<kwd lng="en"><![CDATA[Carcinomatosis]]></kwd>
<kwd lng="en"><![CDATA[Cancer]]></kwd>
<kwd lng="en"><![CDATA[Ovary]]></kwd>
<kwd lng="en"><![CDATA[HIPEC]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goff]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Mandel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Muntz]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Melancon]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ovarian carcinoma diagnosis]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2000</year>
<volume>89</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2068-75</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bouza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chalco]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia y seguridad de la cirugía citorreductora radical con quimioterapia hipertérmica intraperitoneal (CRS+HIPEC) en la carcinomatosis peritoneal [Internet]]]></article-title>
<source><![CDATA[Madrid:Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Morales]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Citorreducción e HIPEC en carcinomatosis peritoneal. Experiencia del Instituto Nacional de Cancerología de México]]></article-title>
<source><![CDATA[Cir Gen]]></source>
<year>2014</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>138-44</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intraperitoneal chemotherapy in ovarian cancer:a review of tolerance and efficacy]]></article-title>
<source><![CDATA[Cancer Manag Res]]></source>
<year>2012</year>
<volume>4</volume>
<page-range>413-22</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaaback]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lawrie]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2011</year>
<volume>11</volume>
<page-range>CD005340</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fagotti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Costantini]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Petrillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vizzielli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fanfani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Margariti]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients:a case-control study on survival in patients with two year follow-up]]></article-title>
<source><![CDATA[Gynecol Oncol]]></source>
<year>2012</year>
<volume>127</volume>
<page-range>502-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
